|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
|
US7910595B2
(en)
*
|
2005-12-21 |
2011-03-22 |
Abbott Laboratories |
Anti-viral compounds
|
|
UA96304C2
(en)
*
|
2006-08-23 |
2011-10-25 |
Кудос Фармасьютикалз Лимитед |
2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
CA2659851C
(en)
*
|
2006-08-23 |
2014-02-25 |
Kudos Pharmaceuticals Limited |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
|
US8236950B2
(en)
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
|
JP2010539239A
(ja)
*
|
2007-09-17 |
2010-12-16 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
|
|
MX2010004074A
(es)
*
|
2007-10-15 |
2010-07-02 |
Astrazeneca Ab |
Combinacion 059.
|
|
CA2710039C
(en)
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
|
AU2009215375A1
(en)
*
|
2008-02-21 |
2009-08-27 |
Astrazeneca Ab |
Combination therapy 238
|
|
MX2010014230A
(es)
*
|
2008-06-20 |
2011-03-29 |
Astrazeneca Ab |
Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.
|
|
EP2318406B1
(en)
|
2008-07-17 |
2016-01-27 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
CA2729045A1
(en)
*
|
2008-07-31 |
2010-02-04 |
Philippe Bergeron |
Pyrimidine compounds, compositions and methods of use
|
|
WO2010049481A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
KR20120107962A
(ko)
|
2009-11-18 |
2012-10-04 |
노파르티스 아게 |
고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물
|
|
WO2011067348A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Mek inhibitor salts and solvates thereof
|
|
WO2011067356A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Polymorphs of a mek inhibitor
|
|
CA2788678C
(en)
|
2010-02-03 |
2019-02-26 |
Signal Pharmaceuticals, Llc |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
EP2539337A1
(en)
*
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
|
KR101461767B1
(ko)
|
2010-03-30 |
2014-11-13 |
노파르티스 아게 |
만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
|
|
EP2552915B1
(en)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Compounds for the treatment of hiv
|
|
EP2558092B1
(en)
|
2010-04-13 |
2018-06-27 |
Novartis AG |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
JP2013529619A
(ja)
|
2010-06-25 |
2013-07-22 |
ノバルティス アーゲー |
タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物
|
|
WO2012099581A1
(en)
|
2011-01-19 |
2012-07-26 |
Takeda Pharmaceutical Company Limited |
Dihydrofuropyrimidine compounds
|
|
HK1199068A1
(en)
|
2011-08-03 |
2015-06-19 |
西格诺药品有限公司 |
Identification of gene expression profile as a predictive biomarker for lkb1 status
|
|
CN102911172A
(zh)
*
|
2011-08-04 |
2013-02-06 |
上海恒瑞医药有限公司 |
杂芳基并嘧啶类衍生物、其制备方法和用途
|
|
CN103374021B
(zh)
*
|
2012-04-21 |
2015-10-28 |
通化济达医药有限公司 |
含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
NZ706418A
(en)
|
2012-11-29 |
2019-09-27 |
Merck Patent Gmbh |
Azaquinazoline carboxamide derivatives
|
|
WO2014172436A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
|
CN105377299B
(zh)
|
2013-04-17 |
2018-06-12 |
西格诺药品有限公司 |
用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
|
|
CA2909629C
(en)
|
2013-04-17 |
2022-12-13 |
Signal Pharmaceuticals, Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
|
US9630966B2
(en)
|
2013-04-17 |
2017-04-25 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
CA2908742C
(en)
|
2013-04-17 |
2021-06-01 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
|
US9505764B2
(en)
|
2013-04-17 |
2016-11-29 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
CA2909579A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
|
NZ629486A
(en)
|
2013-05-29 |
2017-11-24 |
Signal Pharm Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
US9512129B2
(en)
|
2014-04-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
|
|
TWI656121B
(zh)
|
2014-08-04 |
2019-04-11 |
德商拜耳製藥公司 |
２－（嗎啉－４－基）－１，７－萘啶
|
|
CN106008559B
(zh)
*
|
2015-03-25 |
2020-10-16 |
中国科学院上海药物研究所 |
取代吡啶并嘧啶类化合物的合成工艺
|
|
WO2018144791A1
(en)
*
|
2017-02-03 |
2018-08-09 |
Millennium Pharmaceuticals, Inc. |
Combination of vps34 inhibitors and mtor inhibitors
|
|
TWI787284B
(zh)
|
2017-06-22 |
2022-12-21 |
美商西建公司 |
以b型肝炎病毒感染表徵之肝細胞癌之治療
|
|
JP7340519B2
(ja)
*
|
2017-11-06 |
2023-09-07 |
メッドシャイン ディスカバリー インコーポレイテッド |
ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
|
|
WO2021133509A1
(en)
*
|
2019-12-27 |
2021-07-01 |
Angex Pharmaceutical, Inc. |
Heterocyclic compounds as mtor inhibitors
|
|
TWI885039B
(zh)
|
2020-01-13 |
2025-06-01 |
美商邊際分析公司 |
經取代吡唑并嘧啶及其用途
|
|
WO2021247859A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Yumanity Therapeutics, Inc. |
Pyridopyrimidines and methods of their use
|
|
EP4204412A4
(en)
*
|
2020-08-26 |
2024-10-09 |
InventisBio Co., Ltd. |
HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
|
|
CN117088898B
(zh)
*
|
2022-05-13 |
2026-02-06 |
中国药科大学 |
稠环嘧啶类化合物及其制备方法、药物组合物和应用
|
|
WO2024057013A1
(en)
*
|
2022-09-12 |
2024-03-21 |
Exscientia Ai Limited |
Nlrp3 modulators
|
|
GB202415232D0
(en)
|
2024-10-16 |
2024-11-27 |
Nacamed As |
Composition
|